Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors

被引：22

作者：

Cardinale, Jens ^{[1
]}

Roscher, Mareike ^{[1
]}

Schaefer, Martin ^{[1
]}

Geerlings, Max ^{[1
]}

Benesova, Martina ^{[1
]}

Bauder-Wuest, Ulrike ^{[1
]}

Remde, Yvonne ^{[1
]}

Eder, Matthias ^{[1
]}

Novakova, Zora ^{[2
]}

Motlova, Lucia ^{[2
]}

Barinka, Cyril ^{[2
]}

Giesel, Frederik L. ^{[3
]}

Kopka, Klaus ^{[4
]}

机构：

[1] German Canc Res Ctr, Div Radiopharmaceut Chem, D-69120 Heidelberg, Germany

[2] Czech Acad Sci, Lab Struct Biol, Inst Biotechnol, Vestec 25250, Czech Republic

[3] Univ Hosp Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany

[4] Helmholtz Zentrum Dresden Rossendorf, Inst Radiopharmaceut Canc Res, D-01328 Dresden, Germany

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2020年 / 63卷 / 19期

关键词：

GLUTAMATE-CARBOXYPEPTIDASE-II; UREA-BASED INHIBITORS; PROSTATE-CANCER; PRECLINICAL EVALUATION; RADIATION-DOSIMETRY; DIAGNOSIS; LIGAND; PET/CT; F-18-PSMA-1007; BIODISTRIBUTION;

D O I：

10.1021/acs.jmedchem.9b01479

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer. In the present work, we report on the synthesis and preclinical evaluation of a series of F-18-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617. By applying modifications to the linker structure, insight into the structure-activity relationship could be gained, highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution. Selected compounds were co-crystallized with the PSMA protein and analyzed by X-rays with mixed results. Among these, PSMA-1007 (compound 5) showed the best interaction with the PSMA protein. The respective radiotracer [F-18]PSMA-1007 was translated into the clinic and is, in the meantime, subject of advanced clinical trials.

引用

页码：10897 / 10907

页数：11

共 50 条

[31] Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
Sadahiro Naka
Tadashi Watabe
Kenta Kurimoto
Motohide Uemura
Fumihiko Soeda
Oliver C. Neels
Klaus Kopka
Mitsuaki Tatsumi
Hiroki Kato
Norio Nonomura
Eku Shimosegawa
Jens Cardinale
Frederik L. Giesel
Jun Hatazawa
EJNMMI Radiopharmacy and Chemistry, 5
[32] Preclinical internal radiation dosimetry of [18F]PSMA-1007 and its application for predicting the tumor absorbed dose of PSMA-targeting 177Lu-labeled theranostic tandem
Kim, S.
Kim, H.
Ko, H.
Kim, S.
Song, I.
Park, H.
Yun, M.
Kim, S.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S633 - S633
[33] Diagnostic performance of 18F-labeled PSMA PET/CT in patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis
Yang, Yuan-Yuan
Liu, Zhi-Mou
Peng, Ru-Chen
ACTA RADIOLOGICA, 2023, 64 (10) : 2791 - 2801
[34] Can SUVmax be used to predict the development of anatomical correspondence in bone uptakes detected by 18F-PSMA-1007-PET/CT?
Eklund, L.
Anttinen, M.
Vanhatalo, J.
Malaspina, S.
Noponen, T.
Kemppainen, J.
Bostrom, P.
Seppanen, M.
Ettala, O.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S691 - S691
[35] PSMA-targeted18F-labeled Radiohybrid Inhibitors: Concept, preclinical evaluation and first proof of concept study in men
Wurzer, Alexander
Di Carlo, Daniel
Schmidt, Alexander
Beck, Roswitha
Eiber, Matthias
Schwaiger, Markus
Wester, Hans
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[36] 18F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cance
Lee, Byoung Se
Chu, So Young
Jung, Woon Jung
Jeong, Hyeon Jin
Lee, Kyongkyu
Kim, Min Hwan
Kim, Mi Hyun
Chi, Dae Yoon
Ahn, Heesu
Lee, Yong Jin
Lee, Kyo Chul
Lim, Sang Moo
PROSTATE, 2020, 80 (16): : 1383 - 1393
[37] False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake
Hartrampf, Philipp E.
Seitz, Anna Katharina
Krebs, Markus
Buck, Andreas K.
Lapa, Constantin
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (08) : 2044 - 2046
[38] False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake
Philipp E. Hartrampf
Anna Katharina Seitz
Markus Krebs
Andreas K. Buck
Constantin Lapa
European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2044 - 2046
[39] Synthesis and comparative evaluation of three 18F-AmBF3 derivatives of Glu-ureido-Lys for imaging PSMA expression in prostate cancer with positron emission tomography
Kuo, H.
Pan, J.
Merkens, H.
Lau, J.
Zhang, C.
Liu, Z.
Perrin, D. M.
Benard, F.
Lin, K.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S13 - S13
[40] Application of 18F-labeled PSMA-imaging using [18F]DCFPyL at very low PSA-values may allow curative treatment in recurrent prostate cancer
Drzezga, Alexander
Kobe, Carsten
Schmidt, Matthias
Kuhnert, Georg
Zlatopolskiy, Boris
Neumaier, Bernd
Dietlein, Markus
JOURNAL OF NUCLEAR MEDICINE, 2016, 57

← 1 2 3 4 5 →